Checked Nov 20, 2026Start a new check

What was checked

A cancer vaccine designed using each patient’s own tumor mutations reduced risk of melanoma returning or death by 42% in 1,137-person trial (82% vs 70% alive without recurrence)

Assessment summary

Accurate

The INTerpath-001 trial enrolled exactly 1,137 patients with high-risk melanoma, as confirmed by multiple independent sources including clinical trial registries and medical institutions.

Key findings

Model assessments

Assessment summary

  • The reported trial size, 42% relative reduction, and two-year recurrence-free rates of 82.2% versus 70.0% are supported by multiple reports medicalxpress.com nature.com.
  • However, the claim describes the vaccine as reducing the risk of “melanoma returning or death” while pairing that with the percentage “alive without recurrence,” which is recurrence-free survival rather than overall survival nature.com clinicallab.com.

Claims reviewed

The 82% versus 70% figures demonstrate that the treatment reduced overall mortality by 42%.

Needs context
The figures measure being alive without recurrence, a recurrence-free-survival endpoint, not overall survival. The 42% figure refers to the relative risk of recurrence or death, so the wording can incorrectly imply a proven 42% reduction in deaths alone nature.com clinicallab.com.

This claim may mislead readers without added context.

A cancer vaccine was designed using each patient’s own tumor mutations.

Supported
The reported personalized mRNA vaccine was tailored to mutations identified in each patient’s tumor clinicallab.com arstechnica.com.

The treatment reduced the risk of melanoma returning or death by 42%.

Supported
Reported results show a 42% relative reduction in the risk of recurrence or death versus pembrolizumab alone, with a reported hazard ratio of 0.58 nature.com clinicallab.com.

Assessment summary

  • All major factual claims are accurate and well-supported by recent clinical trial data.
  • The 42% risk reduction, trial size of 1,137 patients, and the 82% vs 70% survival rates are consistently reported across multiple credible medical sources covering the INTerpath-001 Phase 3 trial results announced in October 2026.

Claims reviewed

Cancer vaccine designed using each patient's own tumor mutations

Supported
Multiple sources confirm the vaccine (intismeran autogene) is personalized, using next-generation sequencing to identify patient-specific tumor mutations and neoantigens to create individualized mRNA vaccines.

Reduced risk of melanoma returning or death by 42%

Supported
This 42% risk reduction is consistently reported across all major medical sources covering the INTerpath-001 Phase 3 trial results, comparing the vaccine plus pembrolizumab group to pembrolizumab alone.

82% vs 70% alive without recurrence

Supported
At two years, 82.2% (rounded to 82%) of vaccine recipients were alive without recurrence compared to 70% in the control group receiving pembrolizumab plus placebo, consistently reported across sources.

Assessment summary

  • All major factual elements are supported by multiple reliable reports.
  • The phase 3 INTerpath-001 trial of the individualized mRNA neoantigen vaccine (intismeran autogene) plus pembrolizumab reported a hazard ratio equivalent to a 42% reduction in risk, enrolled 1,137 patients, and showed 24-month recurrence-free survival of about 82% versus 70%.
  • Sources include peer-reviewed coverage and major cancer/medical organizations.

Claims reviewed

The vaccine reduced risk of melanoma returning or death by 42%

Supported
The trial reported a hazard ratio corresponding to a 42% reduction in the risk of recurrence or death for the vaccine-plus-pembrolizumab arm versus pembrolizumab alone. jamanetwork.com esmo.org

Recurrence-free survival was 82% vs 70% alive without recurrence

Supported
The published 24-month recurrence-free survival estimates were about 82.2% for the vaccine-plus-pembrolizumab group versus 70.0% for pembrolizumab alone. jamanetwork.com esmo.org

A cancer vaccine was designed using each patient’s own tumor mutations

Supported
The investigational therapy is an individualized neoantigen mRNA vaccine manufactured from sequencing each patient’s tumor to select personal tumor-specific mutations (neoantigens). jamanetwork.com esmo.org

Sources cited

28 sources

Share this result